# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the...
A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infri...
HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a Buy and maintains $7 price t...
- Reuters
HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a Buy and maintains $7 price t...
Second Quarter and Full Year 2024 Financial Outlook Second Quarter 2024Full Year 2024Net Product Revenue$43 -45 million$183 - $...
Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(...